| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.75 [1.10, 2.78] | | < 1 | | 0% | 2 studies (2/-) | 0.9 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.44 [1.05, 1.97] | | < 1 | | 0% | 2 studies (2/-) | 1.3 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.88 [0.56, 1.39] | | > 1 | | 0% | 2 studies (2/-) | 29.5 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 0.93 [0.65, 1.31] | | > 1 | | 0% | 2 studies (2/-) | 33.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.82 [0.66, 5.02] | | < 1 | | 15% | 2 studies (2/-) | 12.5 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.97 [1.37, 2.81] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 2.53 [0.90, 7.11] | | < 1 | | 44% | 2 studies (2/-) | 3.9 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.62 [1.45, 4.72] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.88 [1.33, 2.65] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 3.00 [0.60, 15.11] | | < 1 | | 0% | 1 study (1/-) | 9.2 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 2.91 [1.43, 5.93] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.99 [0.18, 22.07] | | < 1 | | 0% | 2 studies (2/-) | 28.9 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 3.09 [0.28, 33.55] | | < 1 | | 0% | 2 studies (2/-) | 17.9 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.06, 15.92] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.33 [0.20, 26.64] | | < 1 | | 0% | 2 studies (2/-) | 25.0 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.47 [0.11, 19.26] | | < 1 | | 0% | 2 studies (2/-) | 38.5 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.48 [0.11, 19.36] | | < 1 | | 0% | 2 studies (2/-) | 38.4 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 13.65 [1.74, 107.28] | | < 1 | | 0% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.47 [0.11, 19.26] | | < 1 | | 0% | 2 studies (2/-) | 38.5 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 1.52 [0.87, 2.65] | | < 1 | | 0% | 2 studies (2/-) | 7.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.54 [0.04, 8.08] | | < 1 | | 65% | 2 studies (2/-) | 67.2 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 2.91 [0.29, 28.87] | | < 1 | | 0% | 2 studies (2/-) | 18.3 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 0.67 [0.05, 8.73] | | < 1 | | 0% | 2 studies (2/-) | 62.0 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.64 [0.11, 3.91] | | < 1 | | 0% | 1 study (1/-) | 68.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.45 [0.27, 21.97] | | < 1 | | 39% | 2 studies (2/-) | 21.3 % | some concern | not evaluable | moderate | non important | - |
| Dizziness AE (grade 3-4) | 2.03 [0.07, 60.94] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.78 [0.05, 60.46] | | < 1 | | 73% | 2 studies (2/-) | 37.6 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.34 [0.01, 11.05] | | < 1 | | 79% | 2 studies (2/-) | 72.4 % | some concern | not evaluable | moderate | non important | - |
| Headache AE (grade 3-4) | 1.01 [0.02, 51.24] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 3.13 [0.62, 15.84] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.71 [0.26, 11.34] | | < 1 | | 0% | 2 studies (2/-) | 29.0 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 1.48 [0.83, 2.63] | | < 1 | | 36% | 2 studies (2/-) | 9.3 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.99 [0.09, 10.99] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia AE (grade 3-4) | 1.16 [0.62, 2.15] | | < 1 | | 0% | 2 studies (2/-) | 32.3 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 1.21 [0.04, 36.28] | | < 1 | | 71% | 2 studies (2/-) | 45.6 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 6.04 [0.72, 50.82] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.87 [0.75, 4.63] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 3.93 [0.18, 87.94] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
